These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26761707)

  • 1. Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.
    Fullen DJ; Noulin N; Catchpole A; Fathi H; Murray EJ; Mann A; Eze K; Balaratnam G; Borley DW; Gilbert A; Lambkin-Williams R
    PLoS One; 2016; 11(1):e0145902. PubMed ID: 26761707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy Volunteer Human Challenge Model.
    Han A; Czajkowski LM; Donaldson A; Baus HA; Reed SM; Athota RS; Bristol T; Rosas LA; Cervantes-Medina A; Taubenberger JK; Memoli MJ
    Clin Infect Dis; 2019 Nov; 69(12):2082-2090. PubMed ID: 30770534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets.
    Houser KV; Pearce MB; Katz JM; Tumpey TM
    J Virol; 2013 Dec; 87(24):13480-9. PubMed ID: 24089569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
    Fiore AE; Uyeki TM; Broder K; Finelli L; Euler GL; Singleton JA; Iskander JK; Wortley PM; Shay DK; Bresee JS; Cox NJ;
    MMWR Recomm Rep; 2010 Aug; 59(RR-8):1-62. PubMed ID: 20689501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Apr; 61(14):237-41. PubMed ID: 22495226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
    Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
    Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
    Heldens J; Hulskotte E; Voeten T; Breedveld B; Verweij P; van Duijnhoven W; Rudenko L; van Damme P; van den Bosch H
    Vaccine; 2014 Sep; 32(39):5118-24. PubMed ID: 24858566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: Blind, randomized, and placebo-controlled trial.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Abitay R; Nurpeisova A; Sagymbay A; Koshemetov Z; Stukova M; Buzitskaya Z; Кulmagambetov I; Karabayeva D; Davlyatshin T; Khairullin B
    J Med Virol; 2018 Jan; 90(1):41-49. PubMed ID: 28842994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.
    Watson JM; Francis JN; Mesens S; Faiman GA; Makin J; Patriarca P; Treanor JJ; Georges B; Bunce CJ
    Virol J; 2015 Feb; 12():13. PubMed ID: 25645025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase IV: randomized controlled trial to evaluate lot consistency of trivalent split influenza vaccines in healthy adults.
    Song JY; Cheong HJ; Lee J; Wie SH; Park KH; Kee SY; Jeong HW; Kim YS; Noh JY; Choi WS; Park DW; Sohn JW; Kim WJ
    Hum Vaccin Immunother; 2014; 10(10):2958-64. PubMed ID: 25483462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
    Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
    AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Tool for Investigating Asthma and COPD Exacerbations: A Newly Manufactured and Well Characterised GMP Wild-Type Human Rhinovirus for Use in the Human Viral Challenge Model.
    Fullen DJ; Murray B; Mori J; Catchpole A; Borley DW; Murray EJ; Balaratnam G; Gilbert A; Mann A; Hughes F; Lambkin-Williams R
    PLoS One; 2016; 11(12):e0166113. PubMed ID: 27936016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 Randomized Trial of the Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Virus Challenge Model.
    McBride JM; Lim JJ; Burgess T; Deng R; Derby MA; Maia M; Horn P; Siddiqui O; Sheinson D; Chen-Harris H; Newton EM; Fillos D; Nazzal D; Rosenberger CM; Ohlson MB; Lambkin-Williams R; Fathi H; Harris JM; Tavel JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.